

**Table S1. Solicited Local Adverse Events after the Booster Dosing**

	<b>Group A: Two Prior Doses of MVC-COV1901</b>				<b>Group B: Three Prior Doses of MVC-COV1901</b>			
	<b>MVC-COV1901 (15 mcg) (N = 15), n (%)</b>	<b>MVC-COV1901 (15 mcg, Beta) (N = 15), n (%)</b>	<b>MVC-COV1901 (25 mcg, Beta) (N = 15), n (%)</b>	<b>All Participants (N = 45), n (%)</b>	<b>MVC-COV1901 (15 mcg) (N = 21), n (%)</b>	<b>MVC-COV1901 (15 mcg, Beta) (N = 21), n (%)</b>	<b>MVC-COV1901 (25 mcg, Beta) (N = 20), n (%)</b>	<b>All Participants (N = 62), n (%)</b>
<b>Any Solicited Local AEs</b>	10 (66.7)	11 (73.3)	9 (60.0)	30 (66.7)	13 (61.9)	12 (57.1)	14 (70.0)	39 (62.9)
Grade 1	10 (66.7)	11 (73.3)	8 (53.3)	29 (64.4)	13 (61.9)	11 (52.4)	14 (70.0)	38 (61.3)
Grade 2	0	0	1 (6.7)	1 (2.2)	0	1 (4.8)	0	1 (1.6)
Grade 3	0	0	0	0	0	0	0	0
<b>Pain/Tenderness</b>	10 (66.7)	11 (73.3)	9 (60.0)	30 (66.7)	13 (61.9)	12 (57.1)	14 (70.0)	39 (62.9)
Grade 1	10 (66.7)	11 (73.3)	8 (53.3)	29 (64.4)	13 (61.9)	11 (52.4)	14 (70.0)	38 (61.3)
Grade 2	0	0	1 (6.7)	1 (2.2)	0	1 (4.8)	0	1 (1.6)
Grade 3	0	0	0	0	0	0	0	0
<b>Erythema/Redness</b>	1 (6.7)	0	1 (6.7)	2 (4.4)	0	0	0	0
Grade 1	1 (6.7)	0	1 (6.7)	2 (4.4)	0	0	0	0
Grade 2	0	0	0	0	0	0	0	0
Grade 3	0	0	0	0	0	0	0	0
<b>Induration/Swelling</b>	2 (13.3)	0	3 (20.0)	5 (11.1)	0	1 (4.8)	1 (5.0)	2 (3.2)
Grade 1	2 (13.3)	0	3 (20.0)	5 (11.1)	0	0	1 (5.0)	1 (1.6)
Grade 2	0	0	0	0	0	1 (4.8)	0	1 (1.6)
Grade 3	0	0	0	0	0	0	0	0

Abbreviations: N = number of subjects in the population; n = number of subjects in the specific category. % = percentage of subjects with N as the denominator.

**Table S2. Solicited Systemic Adverse Events after the Booster Dosing**

	<b>Group A: Two Prior Doses of MVC-COV1901</b>				<b>Group B: Three Prior Doses of MVC-COV1901</b>			
	<b>MVC-COV1901 (15 mcg) (N = 15), n (%)</b>	<b>MVC-COV1901 (15 mcg, Beta) (N = 15), n (%)</b>	<b>MVC-COV1901 (25 mcg, Beta) (N = 15), n (%)</b>	<b>All Participants (N = 45), n (%)</b>	<b>MVC-COV1901 (15 mcg) (N = 21), n (%)</b>	<b>MVC-COV1901 (15 mcg, Beta) (N = 21), n (%)</b>	<b>MVC-COV1901 (25 mcg, Beta) (N = 20), n (%)</b>	<b>All Participants (N = 62), n (%)</b>
<b>Any Solicited Systemic AEs</b>	9 (60.0)	9 (60.0)	9 (60.0)	27 (60.0)	9 (42.9)	7 (33.3)	13 (65.0)	29 (46.8)
Grade 1	7 (46.7)	8 (53.3)	6 (40.0)	21 (46.7)	7 (33.3)	6 (28.6)	12 (60.0)	25 (40.3)
Grade 2	1 (6.7)	1 (6.7)	2 (13.3)	4 (8.9)	2 (9.5)	1 (4.8)	0	3 (4.8)
Grade 3	1 (6.7)	0	1 (6.7)	2 (4.4)	0	0	1 (5.0)	1 (1.6)
<b>Fever</b>	1 (6.7)	0	1 (6.7)	2 (4.4)	0	0	1 (5.0)	1 (1.6)
Grade 1	1 (6.7)	0	1 (6.7)	2 (4.4)	0	0	0	0
Grade 2	0	0	0	0	0	0	1 (5.0)	1 (1.6)
Grade 3	0	0	0	0	0	0	0	0
<b>Malaise/Fatigue</b>	5 (33.3)	7 (46.7)	8 (53.3)	20 (44.4)	7 (33.3)	6 (28.6)	8 (40.0)	21 (33.9)
Grade 1	3 (20.0)	7 (46.7)	5 (33.3)	15 (33.3)	5 (23.8)	5 (23.8)	7 (35.0)	17 (27.4)
Grade 2	1 (6.7)	0	2 (13.3)	3 (6.7)	2 (9.5)	1 (4.8)	0	3 (4.8)
Grade 3	1 (6.7)	0	1 (6.7)	2 (4.4)	0	0	1 (5.0)	1 (1.6)
<b>Myalgia</b>	4 (26.7)	3 (20.0)	5 (33.3)	12 (26.7)	5 (23.8)	1 (4.8)	7 (35.0)	13 (21.0)
Grade 1	3 (20.0)	2 (13.3)	4 (26.7)	9 (20.0)	5 (23.8)	1 (4.8)	7 (35.0)	13 (21.0)
Grade 2	1 (6.7)	1 (6.7)	1 (6.7)	3 (6.7)	0	0	0	0
Grade 3	0	0	0	0	0	0	0	0
<b>Headache</b>	5 (33.3)	2 (13.3)	4 (26.7)	11 (24.4)	3 (14.3)	3 (14.3)	4 (20.0)	10 (16.1)
Grade 1	4 (26.7)	2 (13.3)	3 (20.0)	9 (20.0)	3 (14.3)	3 (14.3)	3 (15.0)	9 (14.5)

	<b>Group A: Two Prior Doses of MVC-COV1901</b>				<b>Group B: Three Prior Doses of MVC-COV1901</b>			
	<b>MVC-COV1901 (15 mcg) (N = 15), n (%)</b>	<b>MVC-COV1901 (15 mcg, Beta) (N = 15), n (%)</b>	<b>MVC-COV1901 (25 mcg, Beta) (N = 15), n (%)</b>	<b>All Participants (N = 45), n (%)</b>	<b>MVC-COV1901 (15 mcg) (N = 21), n (%)</b>	<b>MVC-COV1901 (15 mcg, Beta) (N = 21), n (%)</b>	<b>MVC-COV1901 (25 mcg, Beta) (N = 20), n (%)</b>	<b>All Participants (N = 62), n (%)</b>
Grade 2	1 (6.7)	0	1 (6.7)	2 (4.4)	0	0	1 (5.0)	1 (1.6)
Grade 3	0	0	0	0	0	0	0	0
<b>Nausea/Vomiting</b>	2 (13.3)	1 (6.7)	2 (13.3)	5 (11.1)	0	0	1 (5.0)	1 (1.6)
Grade 1	1 (6.7)	1 (6.7)	2 (13.3)	4 (8.9)	0	0	1 (5.0)	1 (1.6)
Grade 2	1 (6.7)	0	0	1 (2.2)	0	0	0	0
Grade 3	0	0	0	0	0	0	0	0
<b>Diarrhea</b>	5 (33.3)	1 (6.7)	2 (13.3)	8 (17.8)	1 (4.8)	3 (14.3)	5 (25.0)	9 (14.5)
Grade 1	4 (26.7)	1 (6.7)	2 (13.3)	7 (15.6)	1 (4.8)	2 (9.5)	5 (25.0)	8 (12.9)
Grade 2	0	0	0	0	0	1 (4.8)	0	1 (1.6)
Grade 3	1 (6.7)	0	0	1 (2.2)	0	0	0	0

Abbreviations: N = number of subjects in the population; n = number of subjects in the specific category. % = percentage of subjects with N as the denominator.

**Table S3. Summary of Unsolicited Adverse Events and Other Adverse Events**

	<b>Group A: Two Prior Doses of MVC-COV1901</b>				<b>Group B: Three Prior Doses of MVC-COV1901</b>			
	<b>MVC-COV1901 (15 mcg) (N = 15), n (%)</b>	<b>MVC-COV1901 (15 mcg, Beta) (N = 15), n (%)</b>	<b>MVC-COV1901 (25 mcg, Beta) (N = 15), n (%)</b>	<b>All Participants (N = 45), n (%)</b>	<b>MVC-COV1901 (15 mcg) (N = 21), n (%)</b>	<b>MVC-COV1901 (15 mcg, Beta) (N = 21), n (%)</b>	<b>MVC-COV1901 (25 mcg, Beta) (N = 20), n (%)</b>	<b>All Participants (N = 62), n (%)</b>
Unsolicited AEs	4 (26.7)	6 (40.0)	5 (33.3)	15 (33.3)	6 (28.6)	8 (38.1)	3 (15.0)	17 (27.4)
Related Unsolicited AEs	1 (6.7)	1 (6.7)	2 (13.3)	4 (8.9)	2 (9.5)	2 (9.5)	2 (10.0)	6 (9.7)
Unsolicited AEs ≥ Grade 3	0	0	0	0	0	0	0	0
Related Unsolicited AEs ≥ Grade 3	0	0	0	0	0	0	0	0
AEs ≥ Grade 3	0	0	0	0	0	0	0	0
Related AEs ≥ Grade 3	0	0	0	0	0	0	0	0
SAEs	0	0	0	0	0	0	0	0
Related SAEs	0	0	0	0	0	0	0	0
AESI (including pIMD)	0	0	0	0	0	0	0	0
VAED	0	0	0	0	0	0	0	0
AEs Leading to Intervention Discontinuation	0	0	0	0	0	0	0	0
AEs Leading to Study Withdrawal	0	0	0	0	0	0	0	0
Death	0	0	0	0	0	0	0	0

Abbreviations: N = number of subjects in the population; n = number of subjects with events; AE = Adverse Event; SAE = Serious Adverse Event; AESI = Adverse events of special interest; pIMD = potential immune mediated disorders; VAED = Vaccine-associated enhanced disease.

Table S4. Summary of immunogenicity data for Groups A and B

		Group A					
		MVC-COV1901 (15 mcg) (n=14)		MVC-COV1901-Beta (15 mcg) (n=12)		MVC-COV1901-Beta (25 mcg) (n=12)	
		[GMT]	95% CI	[GMT]	95% CI	[GMT]	95% CI
<b>WT (NT<sub>50</sub>)*</b>	V2 (Day 1)	<b>61.28</b>	(34.48, 108.91)	<b>50.74</b>	(27.26, 94.44)	<b>42.47</b>	(22.82, 79.03)
	V5 (Day 29)	<b>1352.00</b>	(797.38, 2292.40)	<b>1805.02</b>	(1023.61, 3182.94)	<b>3602.75</b>	(2036.68, 6373.05)
<b>WT GMT ratio**</b>	V5/V2	<b>26.29</b>	(15.51, 44.58)	<b>35.10</b>	(19.91, 61.90)	<b>70.06</b>	(39.61, 123.94)
<b>Beta (NT<sub>50</sub>)*</b>	V2 (Day 1)	<b>9.75</b>	(5.57, 17.08)	<b>6.29</b>	(3.43, 11.52)	<b>5.99</b>	(3.27, 10.98)
	V5 (Day 29)	<b>225.59</b>	(128.13, 397.17)	<b>931.34</b>	(509.33, 1703.00)	<b>1476.85</b>	(806.39, 2704.76)
<b>Beta GMT ratio**</b>	V5/V2	<b>30.98</b>	(17.60, 54.55)	<b>127.92</b>	(69.96, 233.91)	<b>202.85</b>	(110.76, 371.51)
<b>Anti-spike IgG (WT)</b>	V2 (Day 1)	<b>1384.95</b>	(876.59, 2188.12)	<b>1301.00</b>	(793.82, 2132.21)	<b>1073.76</b>	(655.17, 1759.79)
	V4 (Day 15)	<b>25878.60</b>	(17387.24, 38516.84)	<b>32938.41</b>	(21459.28, 50558.02)	<b>43208.61</b>	(28085.34, 66475.38)
	V5 (Day 29)	<b>25257.76</b>	(16360.67, 38993.18)	<b>30672.19</b>	(19210.70, 48971.84)	<b>61907.00</b>	(38676.11, 99091.57)
<b>IgG GMT ratio**</b>	V4/V2	<b>20.65</b>	(13.88, 30.74)	<b>26.29</b>	(17.13, 40.35)	<b>34.48</b>	(22.41, 53.05)
	V5/V2	<b>20.16</b>	(13.06, 31.12)	<b>24.48</b>	(15.33, 39.08)	<b>49.41</b>	(30.87, 79.08)
<b>Pseudovirus NT ID<sub>50</sub> (WT)</b>	V2 (Day 1)	<b>45.12</b>	(98.07, 20.76)	<b>35.97</b>	(19.84, 65.21)	<b>40.62</b>	(26.33, 62.66)
	V4 (Day 15)	<b>1520.96</b>	(1023.93, 2259.24)	<b>1723.40</b>	(1227.59, 2419.44)	<b>2315.39</b>	(1879.03, 2853.08)
<b>Pseudovirus NT ID<sub>50</sub> (BA.4/BA.5)</b>	V2 (Day 1)	<b>14.50</b>	(9.39, 22.38)	<b>10.00</b>	(10.00, 10.00)	<b>10.93</b>	(8.99, 13.30)
	V4 (Day 15)	<b>139.11</b>	(76.16, 254.09)	<b>240.10</b>	(137.63, 418.86)	<b>425.65</b>	(272.79, 664.17)
<b>Pseudovirus NT ID<sub>90</sub> (WT)</b>	V2 (Day 1)	<b>18.53</b>	(10.30, 33.33)	<b>14.58</b>	(10.82, 19.63)	<b>14.05</b>	(10.02, 19.68)
	V4 (Day 15)	<b>434.71</b>	(267.37, 706.78)	<b>558.18</b>	(328.24, 949.20)	<b>888.27</b>	(551.22, 1431.43)
<b>Pseudovirus NT ID<sub>90</sub> (BA.4/BA.5)</b>	V2 (Day 1)	<b>11.58</b>	(9.33, 14.38)	<b>10.00</b>	(10.00, 10.00)	<b>10.00</b>	(10.00, 10.00)
	V4 (Day 15)	<b>54.52</b>	(30.41, 97.75)	<b>92.95</b>	(57.80, 149.50)	<b>157.99</b>	(105.15, 237.39)

		Group B					
		MVC-COV1901 (15 mcg) (n=18)		MVC-COV1901-Beta (15 mcg) (n=19)		MVC-COV1901-Beta (25 mcg) (n=18)	
		[GMT]	95% CI	[GMT]	95% CI	[GMT]	95% CI
<b>WT (NT<sub>50</sub>)*</b>	V2 (Day 1)	<b>292.89</b>	(220.46, 389.11)	<b>253.89</b>	(192.56, 334.76)	<b>263.29</b>	(198.18, 349.79)
	V5 (Day 29)	<b>867.93</b>	(629.98, 1195.74)	<b>1124.98</b>	(824.29, 1535.36)	<b>928.54</b>	(680.78, 1266.48)
<b>WT GMT ratio**</b>	V5/V2	<b>3.25</b>	(2.36, 4.47)	<b>4.21</b>	(3.08, 5.74)	<b>3.47</b>	(2.55, 4.74)
<b>Beta (NT<sub>50</sub>)*</b>	V2 (Day 1)	<b>34.02</b>	(21.76, 53.19)	<b>25.09</b>	(16.24, 38.77)	<b>31.17</b>	(19.94, 48.74)
	V5 (Day 29)	<b>147.14</b>	(102.32, 211.61)	<b>459.23</b>	(322.19, 654.56)	<b>323.78</b>	(227.68, 460.43)
<b>Beta GMT ratio**</b>	V5/V2	<b>5.03</b>	(3.49, 7.23)	<b>15.69</b>	(11.01, 22.36)	<b>11.06</b>	(7.78, 15.73)
<b>Anti-spike IgG (WT)</b>	V2 (Day 1)	<b>6712.17</b>	(5261.78, 8562.35)	<b>4620.77</b>	(3645.90, 5856.32)	<b>5307.28</b>	(4160.46, 6770.21)
	V4 (Day 15)	<b>21078.01</b>	(15675.17, 28343.06)	<b>28179.38</b>	(21170.75, 37508.24)	<b>21638.16</b>	(16216.34, 28872.72)
	V5 (Day 29)	<b>19014.66</b>	(14364.79, 25169.70)	<b>24953.2</b>	(19040.94, 32701.23)	<b>21889.96</b>	(16782.37, 28552.02)
<b>IgG GMT ratio**</b>	V4/V2	<b>3.86</b>	(2.87, 5.19)	<b>5.16</b>	(3.87, 6.87)	<b>3.96</b>	(2.97, 5.28)
	V5/V2	<b>3.48</b>	(2.63, 4.61)	<b>4.57</b>	(3.49, 5.99)	<b>4.01</b>	(3.07, 5.23)
<b>Pseudovirus NT ID<sub>50</sub> (WT)</b>	V2 (Day 1)	<b>611.33</b>	(400.87, 932.27)	<b>388.14</b>	(271.86, 554.15)	<b>408.18</b>	(254.72, 654.10)
	V4 (Day 15)	<b>1831.75</b>	(1449.69, 2314.49)	<b>1919.17</b>	(1595.53, 2308.44)	<b>1919.51</b>	(1613.19, 2284.00)
<b>Pseudovirus NT ID<sub>50</sub> (BA.4/BA.5)</b>	V2 (Day 1)	<b>33.28</b>	(23.69, 46.76)	<b>22.31</b>	(15.16, 32.83)	<b>25.66</b>	(19.46, 33.84)
	V4 (Day 15)	<b>136.83</b>	(93.16, 200.95)	<b>222.44</b>	(135.10, 366.22)	<b>154.62</b>	(109.03, 219.28)
<b>Pseudovirus NT ID<sub>90</sub> (WT)</b>	V2 (Day 1)	<b>108.97</b>	(82.54, 143.87)	<b>81.60</b>	(60.18, 110.66)	<b>92.07</b>	(64.51, 131.40)
	V4 (Day 15)	<b>428.68</b>	(308.92, 594.85)	<b>533.7</b>	(360.77, 789.53)	<b>417.94</b>	(328.33, 532.01)
<b>Pseudovirus NT ID<sub>90</sub> (BA.4/BA.5)</b>	V2 (Day 1)	<b>11.85</b>	(9.69, 14.50)	<b>11.46</b>	(9.80, 13.42)	<b>11.35</b>	(9.82, 13.12)
	V4 (Day 15)	<b>50.83</b>	(35.40, 72.98)	<b>84.52</b>	(55.02, 129.83)	<b>63.74</b>	(46.65, 87.10)

\*NT<sub>50</sub> GMT and corresponding CI are calculated using an ANCOVA model with baseline log-titers, BMI (<30 or >=30 kg/m<sup>2</sup>) and comorbidity (yes or no) and sex (male or female) as covariate.

\*\*GMT ratio is defined as the geometric mean of fold increase of post-study intervention titres over the baseline titres